Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (32)
Sandra M. Ihne-Schubert, Malte Kircher, Rudolf A. Werner, Constantin Lapa, Hermann Einsele, Andreas Geier & Torben Schubert. (2023) Vector autoregression: Useful in rare diseases?—Predicting organ response patterns in a rare case of secondary AA amyloidosis. PLOS ONE 18:8, pages e0289921.
Crossref
Crossref
Ufuk İlgen, İsmail Uçar, Güner Kılıç & Orhan Küçükşahin. (2023) AA amyloidosis of unknown aetiology: response to treatment with interleukin-1 inhibitors. Clinical Kidney Journal 16:6, pages 1038-1042.
Crossref
Crossref
Tommy Harty, Michelle O’Shaughnessy & Sinead Harney. (2023) Therapeutics in rheumatology and the kidney. Rheumatology 62:3, pages 1009-1020.
Crossref
Crossref
Augusto Vaglio, Marco Gattorno, Stephen McAdoo, Laura Piera Obici & Gian Marco Ghiggeri. (2023) Editorial: The kidney in auto-immune and auto-inflammatory processes: Definitions, mechanisms, and biomarkers. Frontiers in Medicine 9.
Crossref
Crossref
Jordan Thorne, David Clark, Laurette Geldenhuys, Keigan More, Amanda Vinson & Karthik Tennankore. (2022) Serum Amyloid A Protein–Associated Kidney Disease: Presentation, Diagnosis, and Management. Kidney Medicine 4:8, pages 100504.
Crossref
Crossref
Satoshi Yamashita, Masao Saotome, Takeji Saitoh, Noriyoshi Ogawa & Yuichiro Maekawa. (2022) Long-term effect of tocilizumab on left ventricular hypertrophy and systolic dysfunction in AA amyloidosis with rheumatoid arthritis. Journal of Cardiology Cases 25:3, pages 177-181.
Crossref
Crossref
Jakub Sikora, Tereza Kmochová, Dita Mušálková, Michal Pohludka, Petr Přikryl, Hana Hartmannová, Kateřina Hodaňová, Helena Trešlová, Lenka Nosková, Lenka Mrázová, Viktor Stránecký, Mariia Lunová, Milan Jirsa, Eva Honsová, Surendra Dasari, Ellen D. McPhail, Nelson Leung, Martina Živná, Anthony J. Bleyer, Ivan Rychlík, Romana Ryšavá & Stanislav Kmoch. (2022) A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. Kidney International 101:2, pages 349-359.
Crossref
Crossref
Marina Almenara-Tejederas, Fabiola Alonso-García, Wenceslao Adrián Aguillera-Morales, Francisco de la Prada-Álvares & Mercedes Salgueira-Lazo. (2022) Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosis. Nefrología (English Edition) 42:1, pages 28-32.
Crossref
Crossref
Marina Almenara Tejederas, Fabiola Alonso García, Wenceslao Adrián Aguilera Morales, Francisco de la Prada Álvarez & Mercedes Salgueira Lazo. (2022) La inhibición de la interleucina-6 como posible diana terapéutica en la amiloidosis AA. Nefrología 42:1, pages 22-26.
Crossref
Crossref
Sébastien Ottaviani & Bastien Léger. 2022. L'actualité Rhumatologique 2022. L'actualité Rhumatologique 2022
215
224
.
Ahmed Abdulhameed Abdulgawad, Matthew Nicholson & Hadi Goubran. 2022. Paraproteinemia and Related Disorders. Paraproteinemia and Related Disorders
113
125
.
Jorge Romaní, Alba Perdiguer-Gómez, Mònica Vallhonrat-Munill & Yanel Acosta Baptista. (2021) Síndrome PsPAPASH, amiloidosis secundaria y COVID-19: vivir para contarlo. Piel 36:10, pages 657-659.
Crossref
Crossref
Sh. F. Erdes, D. G. Rumyantseva, E. M. Agafonova, M. M. Urumova, A. S. Starkova & S. O. Krasnenko. (2021) A case of effective use of interleukin 6 inhibitors in patients with ankylosing spondylitis with secondary amyloidosis. Modern Rheumatology Journal 15:4, pages 38-42.
Crossref
Crossref
Jacques Morel, Anne Tournadre, Jérémie Sellam, Yoram Bouhnik, Divi Cornec, Valérie Devauchelle-Pensec, Philippe Dieudé, Philippe Goupille, Nicolas Kluger, Estibaliz Lazaro, Benoit Le Goff, Victor de Lédinghen, Thierry Lequerré, Gaëtane Nocturne, Raphaèle Seror, Marie-Elise Truchetet, Frank Verhoeven, Thao Pham & Christophe Richez. (2021) Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine 88:4, pages 105221.
Crossref
Crossref
Per Eriksson, Johan Mölne, Lina Wirestam & Christopher Sjöwall. (2021) Successful Treatment of AA Amyloidosis in Ankylosing Spondylitis Using Tocilizumab: Report of Two Cases and Review of the Literature. Frontiers in Medicine 8.
Crossref
Crossref
Ju-Yang Jung, Young-Bae Kim, Ji-won Kim, Chang-Hee Suh & Hyoun-Ah Kim. (2021) Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy. Medicine 100:32, pages e26843.
Crossref
Crossref
Masato Sawamura, Naoki Sawa, Hideomi Fujiwara, Masayuki Yamanouchi, Noriko Hayami, Akinari Sekine, Hiroki Mizuno, Eiko Hasegawa, Tatsuya Suwabe, Junichi Hoshino, Keiichi Kinowaki, Takeshi Fujii & Yoshifumi Ubara. (2020) Abatacept Improves Intractable Protein-Losing Enteropathy Secondary to AA Amyloidosis in a Patient With Rheumatoid Arthritis. Mayo Clinic Proceedings: Innovations, Quality & Outcomes 4:6, pages 815-820.
Crossref
Crossref
Ziryab Imad Taha, Mohammed Elmujtba Adam Essa, Asaad Tageldein Idris Abdelhalim, Mohey Aldein Ahmed Elamin Elnour, Allaa Ahmed Osman Eltayeb, Shaza Adel Awad Mohammed Elwakeel & Abdelkareem Abdallah Ahmed. (2020) A Male Case of Renal Amyloidosis. Journal of Exploratory Research in Pharmacology 000:000, pages 1-5.
Crossref
Crossref
Sebastian Lapman, William L Whittier, Rushang Parikh, Yuriy Khanin, Vanesa Bijol, Rimda Wanchoo & Kenar D Jhaveri. (2020) Immune checkpoint inhibitor–associated renal amyloid A amyloidosis: A case series and review of the literature. Journal of Onco-Nephrology 4:1-2, pages 52-58.
Crossref
Crossref
M. Delplanque, J. Pouchot, S. Ducharme-Bénard, B.J Fautrel, A. Benyamine, L. Daniel, T. Gendre, G. Grateau & S. Georgin-Lavialle. (2020) AA amyloidosis secondary to adult onset Still's disease: About 19 cases. Seminars in Arthritis and Rheumatism 50:1, pages 156-165.
Crossref
Crossref
Simon Galmiche, David Buob, Soraya Fellahi, Jean-Philippe Bastard, Gilles Grateau & Sophie Georgin-Lavialle. (2020) Polyarthrite rhumatoïde révélée par une polyadénopathie, une diarrhée et une amylose AA digestive. Revue du Rhumatisme 87:1, pages 74-75.
Crossref
Crossref
Ahmet Ilbay, Abdulsamet Erden, Alper Sari, Berkan Armagan, Burak Yasin Aktas, Ertugrul Cagri Bolek, Umut Kalyoncu & Omer Karadag. (2019) Successful Treatment of Amyloid A–Type Amyloidosis Due to Behçet Disease With Tocilizumab. JCR: Journal of Clinical Rheumatology 25:4, pages e43-e45.
Crossref
Crossref
Simon Galmiche, David Buob, Soraya Fellahi, Jean-Philippe Bastard, Gilles Grateau & Sophie Georgin-Lavialle. (2019) Rheumatoid arthritis revealed by polyadenopathy, diarrhea and digestive AA amyloidosis. Joint Bone Spine 86:3, pages 397-398.
Crossref
Crossref
Michael Voulgarelis, Ioannis Mitroulis & Athanasios G. Tzioufas. 2019. Auto-Inflammatory Syndromes. Auto-Inflammatory Syndromes
297
311
.
Levent Kilic, Abdulsamet Erden, Yusuf Sener, Berkan Armagan, Alper Sari, Umut Kalyoncu, Omer Karadag, Ali Akdogan, Ismail Dogan, Sule Apras Bilgen, Sedat Kiraz & Ihsan Ertenli. (2018) Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis. Biomolecules 8:4, pages 136.
Crossref
Crossref
Andrea Rubbert-Roth, Daniel E. Furst, Jan Michael Nebesky, Angela Jin & Erhan Berber. (2018) A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. Rheumatology and Therapy 5:1, pages 21-42.
Crossref
Crossref
Raghav Bansal, Umer Syed, Jacob Walfish, Joshua Aron & Aaron Walfish. (2018) Small Bowel Amyloidosis. Current Gastroenterology Reports 20:3.
Crossref
Crossref
Ethan Craig & Laura C. Cappelli. (2018) Gastrointestinal and Hepatic Disease in Rheumatoid Arthritis. Rheumatic Disease Clinics of North America 44:1, pages 89-111.
Crossref
Crossref
Songkiat Chantarogh, Soamarat Vilaiyuk, Thipwimol Tim-Aroon & Suchin Worawichawong. (2017) Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review. BMC Nephrology 18:1.
Crossref
Crossref
Sinem Nihal Esatoglu, Gulen Hatemi, Serdal Ugurlu, Aycan Gokturk, Koray Tascilar & Huri Ozdogan. (2017) Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy. Medicine 96:34, pages e7859.
Crossref
Crossref
Ömer Nuri Pamuk, Umut Kalyoncu, Kenan Aksu, Ahmet Omma, Yavuz Pehlivan, Yonca Çağatay, Orhan Küçükşahin, Salim Dönmez, Gözde Yıldırım Çetin, Rıdvan Mercan, Özün Bayındır, Ayşe Çefle, Fatih Yıldız, Ayşe Balkarlı, Levent Kılıç, Necati Çakır, Bünyamin Kısacık, Mustafa Ferhat Öksüz, Veli Çobankara, Ahmet Mesut Onat, Mehmet Sayarlıoğlu, Mehmet Akif Öztürk, Gülsüm Emel Pamuk & Nurullah Akkoç. (2016) A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients. Rheumatology International 36:7, pages 945-953.
Crossref
Crossref
Rosanna Abbate, Nasser M. Al-Daghri, Paolo Andreozzi, Niels Borregaard, Günay Can, Gianluca Caridi, Maren Carstensen-Kirberg, Gabriele Cioni, Enrico Conte, Rosario Cuomo, Marie A. Denis, Gohar Fakhfouri, G. Fakhfouri, Renné Fiasse, Andreas Glenthøj, Georg Goliasch, Thomas Gremmel, Christian Herder, Maria Iemmolo, Zhi-Cheng Jing, Robert Krause, Oreste Marrone, Bartosz Miazgowski, Tomasz Miazgowski, Lorenzo Minchiotti, Kazem Mousavizadeh, Gjin Ndrepepa, Alexander Niessner, Cristina Ogayar Luque, Altan Onat, Ioannis Papassotiriou, Martín Ruiz Ortiz, Shaun Sabico, C. Mary Schooling, Sophia D. Sakka, P. Sołtysiak, Frank L. J. Visseren, Jasmin Wagner, Xiao-Jian Wang & Jan Westerink. (2015) Research update for articles published in EJCI in 2013. European Journal of Clinical Investigation 45:10, pages 1005-1016.
Crossref
Crossref